Xuesaitong oral preparation as adjuvant therapy for treating acute cerebral infarction: A systematic review and meta-analysis of randomized controlled trials

Geng, Hongjiao; Zhang, Lidan; Cui, Xin; Zhang, Cheng; Xie, Yan-Ming

doi:10.1016/j.jep.2021.114849

Cited by 6 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our study did not observe clinical effects or clinical outcomes, many previous studies have confirmed that CPM combined with WM can further improve the benefits of patients with CI or sequelae of CI. For example, in the treatment of CI, Xuesaitong ( Panax notoginseng -based CPM) plus conventional treatment is conditionally recommended for the treatment of acute cerebral infarction to improve the total effective rate, National Institutes of Health Stroke Scale (NIHSS) score, China stroke scale (CSS) score, plasma viscosity (PV), and no serious adverse reactions were reported 19 . A systematic review and meta-analysis of 21 RCTs revealed that the combination of Salvianolate injection ( Salvia miltiorrhiza -based CPM) with WM was associated with a higher overall response rate in the treatment of cerebral infarction compared to WM alone.…”

Section: Discussionmentioning

confidence: 99%

Analysis of online prescription patterns in Chinese patients with sequelae of cerebral infarction: a real-world study

Tang,

Song,

Kuang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Cerebral infarction (CI) is a common cerebrovascular disease worldwide, and the burden caused by the sequelae of CI has increased significantly. However, current treatment guidelines lack standardized recommendations for pharmacotherapy of sequelae of CI. This retrospective study collected and analyzed 1.98 million prescriptions concerning sequelae of CI from patients admitted to Zhiyun Health Internet Hospital in 2022. The mean age of patients was 66.2 ± 11.4 years, and 52.40% were male. 79.73% had one or more comorbidities. For treatment, the prescriptions of 1-, 2- and ≥ 3-drug accounted for 64.55%, 23.77% and 11.68% respectively. Chinese patent medicine (CPM) prescriptions, western medicine (WM) prescriptions, and CPM and WM combined (CPM + WM) prescriptions accounted for 53.81%, 27.33%, and 18.86% respectively. In CPM prescriptions, the most frequently prescribed medications were Salvia miltiorrhiza (34.81%), Ginkgo biloba (24.96%), Panax notoginseng (20.67%), Gastrodia (7.15%) and Ligusticum Wallichii (4.90%). For WM prescriptions, the most commonly prescribed agents were anti-hypertensive (32.82%), anti-thrombotic (16.06%), vasodilator (15.70%), anti-dementia (10.88%), and lipid-lowering (9.58%) drugs. Among CPM + WM prescriptions, 72.61% had CPM/WM = 1, 21.20% had CPM/WM < 1, and 6.19% had CPM/WM > 1. This research utilized real-world data extracted from internet hospitals in China to present valuable evidence of online prescription patterns among patients experiencing sequelae of CI.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of online prescription patterns in Chinese patients with sequelae of cerebral infarction: a real-world study

Tang,

Song,

Kuang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The latest systematic review and meta-analysis (Geng et al, 2022) published in 2022 synthetically assessed the efficacy and safety of XST oral preparation, including eight published RCTs up to August 2021. However, these eight studies were excluded during our screening for the following reasons: probably not RCTs (Li et al, 2013;Wang et al, 2017a) (n = 2), non-target population (Li and Liang, 2002;Mi and Wang, 2009) (n = 2), unclear onset time (Liu et al, 2005;Lu, 2010;Chang and He, 2017) (n = 3), and unavailable full-text report (Lin, 2007) (n = 1).…”

Section: Comparison With Previous Studiesmentioning

confidence: 99%

“…In the past few decades, accumulated evidence has indicated that XST has therapeutic benefits in cases of AIS. Recent meta-analyses of randomized controlled trials (RCTs) ( Zhang et al, 2015 ; Geng et al, 2022 ) have evaluated the efficacy of XST for patients with AIS; however, the findings were discordant and inconclusive. Previous meta-analyses analyzed the efficacy of XST oral preparation or XST injection.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of Panax notoginseng saponins (Xuesaitong) for patients with acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials

Shi,

Feng,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Stroke is the major cause of mortality and permanent disability and is associated with an astonishing economic burden worldwide. In the past few decades, accumulated evidence has indicated that Xuesaitong (XST) has therapeutic benefits in cases of acute ischemic stroke (AIS). Our study aimed to provide the best current body of evidence of the efficacy and safety of XST for patients with AIS.Methods: This is a systematic review and meta-analysis of randomized controlled trials (RCTs). We searched eight electronic databases from inception to 17 July 2023 for relevant RCTs. The investigators independently screened trials, extracted data, and assessed the risk of bias. A meta-analysis was conducted using RevMan 5.3 and STATA 16.0 software.Results: In total, 46 RCTs involving 7,957 patients were included. The results showed that XST improved the long-term functional outcomes with lower modified Rankin Scale (mRS) scores (MD = −0.67; 95% CI [−0.92 to −0.42]; p < 0.00001) and a higher proportion of functional independence (mRS ≤2) (RR = 1.08; 95% CI [1.05 to 1.12]; p < 0.00001). Low-quality evidence indicated that XST improved the activities of daily living (MD = 10.17; 95% CI [7.28 to 13.06]; p < 0.00001), improved the neurological impairment (MD = −3.39; 95% CI [−3.94 to −2.84]; p < 0.00001), and enhanced the total efficiency rate (RR = 1.19; 95% CI [1.15 to 1.23]; p < 0.00001). No significant difference was found in the all-cause mortality or incidence of adverse events between the XST and control groups. The certainty of evidence was estimated as moderate to very low.Conclusion: Presently, the administration of XST within 14 days of AIS is associated with favorable long-term functional outcomes. In addition, XST can improve activities of daily living, alleviate neurological deficits, and has shown good tolerability. However, the current evidence is too weak, and the confidence of evidence synthesis was restricted by the high risk of bias. Given the insufficient evidence, appropriately sized and powered RCTs investigating the efficacy and safety of XST for patients with AIS are warranted.Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=446208, CRD42023446208.

show abstract

Panax notoginseng Saponins Protect Brain Microvascular Endothelial Cells against Oxygen-Glucose Deprivation/Resupply-Induced Necroptosis via Suppression of RIP1-RIP3-MLKL Signaling Pathway

Lei

Zhang

et al. 2022

Neurochem Res

View full text Add to dashboard Cite

Xuesaitong oral preparation as adjuvant therapy for treating acute cerebral infarction: A systematic review and meta-analysis of randomized controlled trials

Cited by 6 publications

References 19 publications

Analysis of online prescription patterns in Chinese patients with sequelae of cerebral infarction: a real-world study

Analysis of online prescription patterns in Chinese patients with sequelae of cerebral infarction: a real-world study

Efficacy and safety of Panax notoginseng saponins (Xuesaitong) for patients with acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials

Panax notoginseng Saponins Protect Brain Microvascular Endothelial Cells against Oxygen-Glucose Deprivation/Resupply-Induced Necroptosis via Suppression of RIP1-RIP3-MLKL Signaling Pathway

Contact Info

Product

Resources

About